type 1 diabetes and glp 1 GLP-1 Receptor Agonists as Treatments for 2 GLP-1 actions and target organs.

They work by: Slowing digestion to extend feelings of fullness Reducing appetite and decreasing cravings Supporting insulin release when needed Limiting excess glucose production Improving overall insulin sensitivity Together, these actions create a metabolic environment that supports steady, sustainable weight loss

In the kidney SGLT1 is responsible for approximately 10% of the transport of luminal glucose and thus inhibiting SGLT1 may facilitate SGLT2 induced loss of glucose in the urine (237,239)

Indication 19.3.6

Entre otros frmacos se encuentran efinopegdutida, un pptido derivado de la oxintomodulina conjugado con fragmento Fc de IgG4 humana de administracin mensual, pemvidutida y mazdutida, que poseen efectos reductores de peso (tabla 1) y de grasa heptica (fig

[DOI] [PubMed] [Google Scholar] 49.Facciorusso A., Straus Takahashi M., Eyileten Postula C., Buccino V.R., Muscatiello N